Navigation Links
BioMarin Announces FDA Approval for Kuvan
Date:12/13/2007

First Specific Drug Therapy Approved for the Treatment of PKU

NOVATO, Calif., Dec. 13 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Kuvan(TM) (sapropterin dihydrochloride) Tablets, the first specific drug therapy approved for the treatment of phenylketonuria (PKU). Shipments to the distribution channel will commence tomorrow, and BioMarin will begin promotion of Kuvan immediately.

"The approval of Kuvan represents an important milestone for PKU patients and their families and also for BioMarin. We are extremely pleased to bring this promising treatment option to market in just a little over three years since the IND filing, and we are now ready for an immediate launch," said Jean-Jacques Bienaime, Chief Executive Officer of BioMarin. "We would like to thank all the patients, their families and physicians, our corporate partners, the FDA, and BioMarin employees for their hard work and dedication in making Kuvan a reality."

"In clinical trials, Kuvan has been shown to help control blood Phe levels in PKU patients, and I am thrilled that this new therapy is now commercially available to the PKU community," stated Dr. Barbara Burton, Professor of Pediatrics, Northwestern University Feinberg School of Medicine; Director, PKU Clinic at Children's Memorial Hospital; and Clinical Investigator in the Kuvan Phase 2 and Phase 3 trials. "With Kuvan now approved, physicians and patients have, for the first time, a drug therapy option to manage the disease."

Kuvan is indicated to reduce blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin (BH4) responsive PKU and is to be used in conjunction with a Phe-restricted diet. To determine if there is a response to Kuvan, the recommended starting dose of Kuvan is 10 mg/kg/day taken once daily for up to a month. If there
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014 New technology in ... could allow physicians to see and assess brain tissue ... according to study authors who released their findings today ... Annual Meeting in Colorado Springs, CO. ... the field of neurointervention, a specialty that facilitates stroke ...
(Date:7/29/2014)... 2014 McGraw-Hill Education Professional, a leading global ... and medical communities, has announced the launch of the ... of the world-renowned medical education platform. ... , available for download onto all iOS and Android ... gain access to valuable AccessMedicine diagnostic resources ...
(Date:7/29/2014)... CITY and TORONTO ... EastGate Acquisitions Corporation (OTCBB: ESAQ), an emerging ... the development of improved novel formulations and ... molecules announces expansion of its pharmaceutical development ... development direction includes large molecule drugs that will ...
Breaking Medicine Technology:New Technology May Improve Visualization Of The Brain During Stroke Treatment 2New Technology May Improve Visualization Of The Brain During Stroke Treatment 3McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 2McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 3EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 2EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 3EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 4
... Seen Since Presentation at ASCO ... Alvespimycin Plus Trastuzumab Plus ... Paclitaxel Regimen, HAYWARD, Calif., Sept. ... a Phase 1 clinical,trial showing that alvespimycin, its second-generation Hsp90 inhibitor,demonstrated antitumor ...
... Sept. 7 Roche announced today that three,clinical data ... for presentation at the 2007 Breast Cancer Symposium in ... abstracts include data from the XeNA (Xeloda in NeoAdjuvant),trial, ... Herceptin in,patients with invasive breast cancer. The third presentation ...
Cached Medicine Technology:Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 2Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 3Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 4Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 5Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium 2Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium 3
(Date:7/29/2014)... have discovered a chemical alteration in a single human ... larger studies, could give doctors a simple blood test ... , The discovery, described online in The American ... gene involved in the function of the brain,s response ... what might otherwise be an unremarkable reaction to the ...
(Date:7/29/2014)... Denver, Colorado (PRWEB) July 29, 2014 Daily ... the author of this program claims that he cured his ... the author decided to share part of his experience. ... nasal polys permanently and naturally in just 4 days. Since ... share it with sufferers from all around the world. ...
(Date:7/29/2014)... Daily Gossip reveals in its Leaky Gut Cure ... and functional medicine practitioner, who spent years looking for a ... suffered from leaky gut, too, so this is what determined ... treatment. , Karen Brimeyer decided to share her story, ... the world. The author of the Leaky Gut Cure program ...
(Date:7/29/2014)... New York (PRWEB) July 29, 2014 ... protecting the rights of victims injured by defective drugs ... has been filed by plaintiffs in Canada who allege ... of cardiovascular events with the low testosterone injection ... on July 22, 2014 in the Ontario Superior Court ...
(Date:7/29/2014)... 29, 2014 Daily Gossip reveals in its ... holistic system that will permanently eliminate all the symptoms associated ... natural treatment will banish symptoms such as mild hearing loss, ... heard by patients will be gone forever. , The method ... The author of this program says that at the end ...
Breaking Medicine News(10 mins):Health News:A blood test for suicide? 2Health News:A blood test for suicide? 3Health News:Nasal Polyps Treatment Miracle Review Reveals How to Cure Nasal Polyps Without Surgery 2Health News:Leaky Gut Cure Review Reveals Karen Brimeyer’s Natural Way to Heal Leaky Gut 2Health News:Class Action Lawsuit in Canada Alleges Manufacturer of Delatestryl Testosterone Injection Failed to Warn of Cardiovascular Risks, Parker Waichman LLP Reports 2Health News:Class Action Lawsuit in Canada Alleges Manufacturer of Delatestryl Testosterone Injection Failed to Warn of Cardiovascular Risks, Parker Waichman LLP Reports 3Health News:Tinnitus Miracle Review Exposes the Only Holistic System for Tinnitus Cure 2
... , ARLINGTON, Va., July 23 During ... Majority Leader Tom Daschle and Blue Dog Democrat Rep. Jason ... in the reform of the U.S. healthcare system. The ... medical equipment and services. The American Association for Homecare hosted ...
... , , , ... ), a leading provider of optical components, modules and subsystems, today announced ... June 27, 2009. Oclaro, Inc. was formed April 27, 2009 from ... Avanex Corporation. , , "Being positive Adjusted ...
... Calif., July 23 Oscar Wright, chief executive officer of United Advocates ... Donuts shop, participated in an interview and debate Wednesday on KTVU,s ... , Oscar Wright released this statement today: , ... the U.S. Small Business Administration, I appreciate an individual,s goal to live ...
... might be slowing down among poor families , THURSDAY, ... low-income families in the United States are considered obese, a ... that the news is not all bad: The childhood obesity ... this group. , Among 2- to 4-year-olds from low-income families, ...
... , , PITTSBURGH, July 23 ... stopping in Pennsylvania throughout the week of July 27-31 at ... access information on programs that provide prescription medicines for free ... 8.2 percent -- compared to 5.1% a year ago -- ...
... a cancer-killing protein, scientists at the University of Kentucky,s Markey ... UK professor of radiation medicine, have determined that the tumor-suppressor ... expressing the Par-4 gene, is in fact secreted by most ... cancer cells by binding to receptors on the cell surface. ...
Cached Medicine News:Health News:Sen. Tom Daschle, Rep. Jason Altmire, Healthcare Experts Tout Homecare as Cost-Effective Solution in the Healthcare Reform Process 2Health News:Sen. Tom Daschle, Rep. Jason Altmire, Healthcare Experts Tout Homecare as Cost-Effective Solution in the Healthcare Reform Process 3Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 2Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 3Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 4Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 5Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 6Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 7Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 8Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 9Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 10Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 11Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 12Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 13Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 14Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 15Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 16Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 17Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 18Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 19Health News:Mental Health Advocates Call for Psycho Donuts to Do the Right Thing 2Health News:1 in 7 Low-Income Preschoolers Is Obese 2Health News:Partnership for Prescription Assistance Prepared to Help Pennsylvania Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help Pennsylvania Workers Hurt by Recession 3Health News:Partnership for Prescription Assistance Prepared to Help Pennsylvania Workers Hurt by Recession 4Health News:Human cells secrete cancer-killing protein, UK study finds 2
Provides the security of suture and ease of automated knot tying for vascular closure of 5-8F....
... The all-new Canon CF-60DSi is an all-digital ... simple configuration, and an efficient workflow. ... mounts -- The Canon EOS-1Ds series SLR digital ... a 11.1 mega pixel resolution and the new ...
... The AIA-360 is a sophisticated Aumated Immunoassay ... This analyzer has a footprint of 16 X ... lbs. Its compact design is ideal for ... STAT testing, such as cardiac panels, as well ...
... a simple one, help physicians serve their ... the physician is provided with significantly useful ... This technical accomplishment is combined with dedicated ... The device features: High ...
Medicine Products: